Shuttle Pharmaceuticals Holdings, Inc. current report, Q1 FY2024

Full document

Business Context and Reporting Period

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 8, 2024
Reporting Period: Single event date (January 8, 2024)

This filing reports a significant clinical development milestone for the Company's investigational new drug (IND) application.

Key Financial Metrics

This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.

Material Changes

The material change reported is regulatory approval to proceed with clinical trials:

  • Event: Receipt of a "Safe to Proceed" letter from the U.S. Food and Drug Administration (FDA).
  • Subject: Phase II study of Ropidoxuridine (IPdR).
  • Indication: Radiation sensitizing agent during radiotherapy for patients with newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT promoter.
  • Impact: The Company is authorized to commence the Phase II study.

Guidance, Outlook, and Risks

Outlook and Management Commentary:

  • The Company is currently finalizing site enrollment for the Phase II study.
  • "First patient, first dose" is expected in the coming months.

Risks and Contingencies:

  • The filing contains forward-looking statements regarding future results, strategy, and plans.
  • Actual results may differ materially due to known and unknown risks, uncertainties, and assumptions.
  • Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made.

Investor Verification Checklist

  • Verify the specific inclusion criteria for the Phase II study (IDH-wildtype glioblastoma with unmethylated MGMT promoter).
  • Monitor the timeline for "first patient, first dose" as the Company finalizes site enrollment.
  • Review the attached Press Release (Exhibit 99.1) for detailed study design information.
  • Consult the most recent Form 10-K or 10-Q for current financial liquidity and cash runway, as this 8-K does not provide financial data.